Research Ethics & Policy Series (REPS): "How the Alzheimers Revolution Impacts the Responsible Conduct of Alzheimer’s Research" - Jason Karlawish, MD

12:00pm - 1:00pm • Hybrid: RCH B102AB, Richards Bldg., 3700 Hamilton Walk (and virtual via Zoom)

2026-01-13 12:00:00 2026-01-13 13:00:00 America/New_York Research Ethics & Policy Series (REPS): "How the Alzheimers Revolution Impacts the Responsible Conduct of Alzheimer’s Research" - Jason Karlawish, MD How the Alzheimers Revolution Impacts the Responsible Conduct of Alzheimer’s Research Jason Karlawish, MD Professor of Medicine, Medical Ethics & Health Policy, and Neurology Co-Director, Penn Memory Center Perelman School of Medicine, University of Pennsylvania Alzheimer’s disease and other diseases that cause dementia are undergoing a revolution in their definition, diagnosis and treatment. Using biomarker tests, a clinician can accurately determine the disease causing cognitive impairments, and for some patients, prescribe treatments that affect the natural history of the disease. These advances hold great promise for the care of patients. They also present challenges to the responsible conduct of research that enrolls these patients. This talk will review these challenges, with attention to nomenclature, return of research results and the selection of control group in clinical trials. Registration required; Lunch provided. Streaming available via Zoom. Hybrid: RCH B102AB, Richards Bldg., 3700 Hamilton Walk (and virtual via Zoom) Penn Medical Ethics

Alzheimer’s disease and other diseases that cause dementia are undergoing a revolution in their definition, diagnosis and treatment. Using biomarker tests, a clinician can accurately determine the disease causing cognitive impairments, and for some patients, prescribe treatments that affect the natural history of the disease. These advances hold great promise for the care of patients. They also present challenges to the responsible conduct of research that enrolls these patients. This talk will review these challenges, with attention to nomenclature, return of research results and the selection of control group in clinical trials.